Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Part of paid clinical trials in La Jolla, California.

Sponsor
Gilead Sciences
Study ID
NCT02136511
Status
Approved For Marketing

Conditions

  • Chronic Lymphocytic Leukemia (CLL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Idelalisib — DRUG
    Idelalisib 150 mg tablet administered orally twice daily
  • Rituximab — DRUG
    Rituximab administered intravenously starting at 375 mg/m\^2 at Week 0 and continuing with a dose of 500 mg/m\^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.

Study Details

This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible for other Gilead-sponsored studies.

Key Dates

Status verified
Oct 2014

Locations (4)

FacilityCityStateZIPSite coordinators
University of California, San Diego - Moores Cancer CenterLa JollaCalifornia92093-0820-
Georgetown UniversityWashington D.C.District of Columbia20007-
Hackensack University Medical CenterHackensackNew Jersey07601-
Weill Cornell Medical CollegeNew YorkNew York10021-

Find similar trials in La Jolla, CA

By research site
University of California, San Diego - Moores Cancer Center· La Jolla, CAGeorgetown University· Washington D.C., DCHackensack University Medical Center· Hackensack, NJWeill Cornell Medical College· New York, NY

Related Studies